STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7

Cancer Cell International
Jiayu ChenWei Zhang


Aberrant STAT1 signaling is observed in human hepatocellular carcinoma (HCC) and has been associated with the modulation of cell proliferation and survival. However, the role of STAT1 signaling in HCC and its underlying mechanism remain elusive. We transiently transfected pcDNA3.1-STAT1 and STAT1 siRNA into SMMC7721 and HepG2 cells. Western blot and qRT-PCR examined the expression of protein and RNA of target genes. Cell viability was assessed using MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. We found that STAT1 overexpression increased protein expression of p53 and Fbxw7, and downregulated the expression of cyclin A, cyclin D1, cyclin E, CDK2, Hes-1 and NF-κB p65. These changes led to growth inhibition and induced G0/G1 cell cycle arrest and apoptosis in SMMC7721 and HepG2 cells. Conversely, ablation of STAT1 had the opposite effect on p53, Fbxw7, Hes-1, NF-κB p65, cyclin A, cyclin D1, cyclin E and CDK2, and improved the viability of SMMC7721 and HepG2 cells. Our data indicate that STAT1 exerts tumor-suppressive effects in hepatocarcinogenesis through induction of G0/G1 cell cycle arrest and apoptosis, and may provide a basis for the design of new therapies for the intervention of HCC in the clinic.


Jun 27, 1997·The Journal of Biological Chemistry·N K OssinaM C Kiefer
Jun 24, 2000·Cell Death and Differentiation·A StephanouD S Latchman
Mar 20, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·K SukM S Lee
Jun 19, 2001·International Journal of Cancer. Journal International Du Cancer·E C ShinJ H Park
Feb 26, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Tsutomu MasakiShigeki Kuriyama
Jun 21, 2003·American Journal of Physiology. Gastrointestinal and Liver Physiology·Won-Ho KimBin Gao
Nov 7, 2003·The Journal of Biological Chemistry·Paul A TownsendAnastasis Stephanou
Nov 19, 2003·The Journal of Biological Chemistry·Juan J Sironi, Toru Ouchi
Feb 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Nikolai N KhodarevRalph R Weichselbaum
Apr 13, 2005·Gastroenterology·Wenyu LinRaymond T Chung
Jan 1, 2009·Nature Reviews. Drug Discovery·Véronique Baud, Michael Karin
Jun 9, 2009·PloS One·Nikolai N KhodarevRalph R Weichselbaum
Jan 24, 2012·Breast Cancer Research : BCR·Szeman Ruby ChanRobert D Schreiber
Apr 24, 2012·Immunity·George R Stark, James E Darnell
May 3, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Kangsheng TuQingguang Liu
Jun 2, 2012·Frontiers in Bioscience (Scholar Edition)·Michael Andrew Nalesnik, George Konstantine Michalopoulos
Jun 19, 2012·The American Journal of Pathology·Catia GiovanniniLuigi Bolondi
Aug 8, 2012·Oncogene·W Vainchenker, S N Constantinescu
Aug 18, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kun WuHong-Yang Wang
Apr 17, 2013·Oncology Reports·Guofu ChenGuangyi Wang

❮ Previous
Next ❯


May 16, 2018·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Zhanchun YangHaihe Wang
Feb 23, 2019·Cancers·Bethsebie Lalduhsaki SailoAjaikumar Bahulayan Kunnumakkara
Oct 27, 2020·Cancer Biomarkers : Section a of Disease Markers·Chenglin LiYanyu Wu
Aug 3, 2021·Frontiers in Oncology·Pin ZhaoShaojun Xing

❮ Previous
Next ❯

Methods Mentioned

flow cytometry
Protein Assay

Software Mentioned

Modifit LT

Related Concepts

Related Feeds


Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis